-+ 0.00%
-+ 0.00%
-+ 0.00%

Alterity Therapeutics Seeks Shareholder Approval for CEO David Stamler's Termination Benefits

PUBT·10/21/2026 10:07:16
Listen to the news
Alterity Therapeutics Seeks Shareholder Approval for CEO David Stamler's Termination Benefits
  • Alterity Therapeutics will seek shareholder approval at its upcoming annual general meeting for termination benefits for CEO and Managing Director David Stamler.
  • The benefits form part of his revised remuneration package, which the board approved effective October 15, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-033045), on October 21, 2026, and is solely responsible for the information contained therein.